

March 31, 2026

Press Release

The Research Foundation for Microbial Diseases of Osaka University
Tanabe Pharma Corporation

Notice of Dissolution of Joint Venture relationship with respect to BIKEN Co., Ltd.

The Research Foundation for Microbial Diseases of Osaka University (Head Office: Osaka; Chairperson of the Board: Yoshihiro Yoneda; hereinafter “BIKEN Foundation”) and Tanabe Pharma Corporation (Head Office: Osaka; Representative Director, CEO: Akihisa Harada; hereinafter “Tanabe Pharma”) have agreed to dissolve their joint venture relationship, with respect to BIKEN Co., Ltd. (Head Office: Kagawa Prefecture; President & Representative Director, Takashi Tanaka; Equity ratio: BIKEN Foundation 66.6%, Tanabe Pharma 33.4%) and have entered into a share transfer agreement. Accordingly, BIKEN Foundation will acquire all shares of BIKEN Co., Ltd. held by Tanabe Pharma on April 1, 2026 and make BIKEN Co., Ltd. a wholly owned subsidiary.

1. Background and circumstances

BIKEN Co., Ltd. was established in 2017 as a joint venture with Tanabe Pharma, by spinning off BIKEN Foundation’s production division into a separate company, with the objective of strengthening its production base. Since then, centered on BIKEN Foundation’s vaccine manufacturing technology, BIKEN Co., Ltd. has pursued the deployment of Tanabe Pharma’s pharmaceutical production systems and management methods. Having achieved a certain level of success in their initial objective of strengthening the production base for stable supply, the two partners have decided to dissolve the joint venture agreement.

2. Future business operations

Following the dissolution of the joint venture relationship, BIKEN Foundation will acquire all shares of BIKEN Co., Ltd. held by Tanabe Pharma and make BIKEN Co., Ltd. a wholly owned subsidiary. BIKEN Foundation, the supplier of the largest number of products among Japan’s vaccine manufacturers, will build the optimal business structure to fulfill its mission of “protecting the precious lives around the world through excellent vaccines” vigorously over the long term, regardless of changes in its environment.

BIKEN Foundation and Tanabe Pharma will continue their strong cooperative relationship going forward, as manufacturer and distributor respectively.

3. Overview of BIKEN Co., Ltd. (after changes)

- | | | | |
|-----|----------------------|---|---|
| (1) | Name | : | BIKEN Co., Ltd. (no change) |
| (2) | Address | : | 4-1-70 Seto-cho, Kanonji City, Kagawa Prefecture, 768-0065 |
| (3) | Representative | : | TANAKA Takashi ; President & Representative Director (retains current position) |
| (4) | Business description | : | Manufacture and supply of vaccines and other biological |

- products
- (5) Capital : 100 million yen
 - (6) Date of signing of basic agreement : November 7, 2016
 - (7) Date of signing of final agreement : May 1, 2017
 - (8) Date of establishment : May 9, 2017
 - (9) Commencement of operations and joint venture : September 1, 2017

For inquiries regarding this matter, contact:

PR Section, The Research Foundation for Microbial Diseases of Osaka University TEL: +81-6-6877-4802

PR Group, CEO Office, Tanabe Pharma Corporation TEL: +81-6-6205-5119